Theravance Inc  

(Public, NASDAQ:THRX)   Watch this stock  
Find more results for THRX
16.75
-0.38 (-2.22%)
After Hours: 16.50 -0.25 (-1.49%)
Apr 20, 7:57PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.55 - 17.30
52 week 10.58 - 31.80
Open 17.30
Vol / Avg. 0.00/809,256.00
Mkt cap 2.00B
P/E     -
Div/yield 0.25/5.97
EPS -0.66
Shares 116.62M
Beta 2.21
Inst. own 87%
May 22, 2015
Theravance Inc Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
May 4, 2015
Q1 2015 Theravance Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Apr 24, 2015
Theravance Inc Annual Shareholders Meeting - 5:00PM EDT - Add to calendar
Mar 4, 2015
Theravance Inc at Cowen Health Care Conference
Feb 18, 2015
Q4 2014 Theravance Inc Earnings Call
Feb 18, 2015
Q4 2014 Theravance Inc Earnings Release
Feb 12, 2015
Theravance Inc at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -218.76% -871.93%
Operating margin 1.79% -402.34%
EBITD margin - -257.96%
Return on average assets -11.88% -12.23%
Return on average equity - -194.08%
Employees 10 -
CDP Score - -

Address

951 Gateway Blvd
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2389600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Theravance, Inc. is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The Company operates in a single segment, which is focused on the discovery, development and commercialization of small molecule medicines across different therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company�s key programs include: RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, "FF/VI"), ANORO ELLIPTA (umeclidinium bromide/vilanterol, "UMEC/VI") and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with Glaxo Group Limited (GSK), and Long-Acting Muscarinic Antagonist program. Manufacturing of RELVAR/BREO ELLIPTA (FF/VI) and ANORO ELLIPTA (UMEC/VI) and for the MABA program is handled by GSK.

Officers and directors

William H. Waltrip Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Eric D'Esparbes Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
George B. Abercrombie Senior Vice President - Corporate Partnerships, Commercial
Age: 59
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President - Corporate Partnerships, Clinical and Medical Affairs
Bio & Compensation  - Reuters
Michael W. Aguiar President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Catherine J. Friedman Independent Director
Age: 54
Bio & Compensation  - Reuters
Terrence C. Kearney Independent Director
Age: 60
Bio & Compensation  - Reuters
Paul Pepe Independent Director
Age: 56
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 62
Bio & Compensation  - Reuters